Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 886 to 900 of 2042 results for guidelines

  1. Management of emergency department patients during the COVID-19 pandemic (Word)

    additional support if their condition worsens see NICE's COVID 19 rapid guideline on managing COVID 19 for recommendations on...

  2. NICE health technology evaluation topic selection: the manual (PMG37)

    This is not the current manual. From 29 May 2024, health technologies are selected using the new NICE-wide topic prioritisation process (PMG46)

  3. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  4. Promoting independence through intermediate care

    Promoting independence through intermediate care - a quick guide for staff delivering intermediate care services.

  5. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

  6. Diabetes: statins for secondary prevention of CVD (IND184)

    This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM163

  7. Pregnancy and neonates: breastfeeding 48 hours (IND20)

    This indicator covers the percentage of mothers who give their babies breast milk in the first 48 hours after delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG33

  8. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

  9. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.

  10. Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

    Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults.

  11. ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment (HTE5)

    Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management....

  12. Highly specialised technologies evaluation committee

    Collaborating Centre (a group commissioned by NICE to develop clinical guidelines), if relevant research groups working in the area...

  13. Into practice

    Tools and resources to help you implement guidance and quality standards at work.

  14. Into practice

    Tools and resources to help you implement guidance and quality standards at work.

  15. Migraine prophylaxis: flunarizine (ESUOM33)

    Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making